Mike Aicher

Mr. Aicher is currently Executive Chairman of Roswell Biotechnologies, a molecular electronics company, digitizing biology with molecular electronics to elucidate, diagnose and treat disease, is a Founder of Alveo Technologies, a company focused on solving global health challenges, an Executive Director at Genetic Signatures (ASX: GSS), a company providing innovative molecular diagnostics solutions, is Chairman of CytoBay, a company developing novel oncology solutions and serves on the Board of Directors for Techcyte, a company providing Artificial Intelligence powered diagnostic solutions. Mike previously served on the Board of Fabric Genomics, which analyses and interprets genomic information, and was a Board member of Ariosa, a prenatal testing molecular diagnostics company until its acquisition by Roche in 2015. He co-founded and served as National Genetics Institute's (NGI) CEO from 1991 to 2012. NGI became a wholly owned subsidiary of Laboratory Corporation of America (NYSE: LH) in 2000, where he ran the company’s “Esoteric Business Units”, which generated over $1 billion in annual revenue. He holds a Bachelor of Science in Business Administration from the University of Redlands and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young's "Entrepreneur of the Year" award for emerging technologies.